Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.

Tyler McCann is a Principal Medical Science Liaison on the Lung/GI Oncology MSL Team at Daiichi-Sankyo. In this role, Tyler covers the Great Plains region of the US with responsibilities including cultivating and maintaining relationships with Key External Experts (KEEs) and investigators, conducting scientific exchange, and collaborating with internal stakeholders. Prior to joining Daiichi-Sankyo, Tyler was an MSL with Alkermes for 4 years, supporting the development of nemvaleukin alfa (modified IL-2 for the treatment of ovarian cancer and melanoma). Tyler has 10+ years of academic research experience in Molecular Biology and Oncology prior to joining industry, graduating from Vanderbilt University with a PhD in Biomedical Research and completing a Post-Doctoral Fellowship at University of Colorado-Anschutz Medical Campus.